Sino Biopharmaceutical, Boehringer Sign Oncology Deal Worth Up to $7 Billion
Sino Biopharmaceutical said it entered an option and license agreement with Boehringer Ingelheim covering six preclinical oncology programs, with potential milestone payments of $7 billion.
Sino Biopharmaceutical HKEX:1177 said on Wednesday it had entered into an option and license agreement with Germany's Boehringer Ingelheim for six preclinical oncology programs that could generate $7 billion in milestone payments.Here are some more details